BioNTech SE Company Research Report

Company Overview

• Name: BioNTech SE

• Mission: BioNTech SE is committed to improving global health through fundamental research and development of immunotherapies. The company believes in scientific rigor, innovation, and passion as the driving forces behind translating science into survival, with a focus on the immune system's role in fighting cancer, infectious diseases, and other serious diseases.

• Founded: 2008

• Founders: Prof. Ugur Sahin, M.D., Prof. Özlem Türeci, M.D., and Prof. Christoph Huber, M.D.

• Key People:

• Prof. Ugur Sahin, M.D. (CEO)

• Annemarie Hanekamp (CCO)

• Jens Holstein (CFO)

• Sierk Poetting (COO)

• Ryan Richardson (CSO)

• James Ryan (CLO & CBO)

• Prof. Özlem Türeci, M.D. (CMO)

• Headquarters: An der Goldgrube 12, 55131 Mainz, Germany

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: BioNTech is renowned for its pioneering work in mRNA technology and the rapid development of the world's first mRNA vaccine for COVID-19, in collaboration with Pfizer.

Products

• Products Offered:

• COVID-19 Vaccine: The first mRNA vaccine approved for human use, developed rapidly in response to the SARS-CoV-2 pandemic.

• mRNA Therapies: Use mRNA to deliver genetic instructions to cells, facilitating the development of proteins for therapeutic effect, particularly in cancer and infectious disease treatments.

• Engineered Cell Therapies: Include chimeric antigen receptor (CAR) T cell therapies and T cell receptor (TCR) programs aimed at solid tumors.

• Protein-based Therapeutics: Develop next-generation treatments, including mono- and bispecific antibodies for various tumor types.

• Small Molecule Immunomodulators: Small molecules that enhance immunomodulation in cancer therapies.

• High-level Description and Key Features:

• mRNA Therapies: Deliver genetic information to cells, promoting protein synthesis for therapeutic purposes.

• Engineered Cell Therapies: Modify patient T cells to target cancer-specific antigens, innovating CAR-T cell persistence.

• Protein-based Therapeutics: Utilize antibodies and antibody-drug conjugates for targeted cancer treatments.

• Small Molecule Immunomodulators: Induce discrete patterns of immunomodulation for cancer therapy enhancement.

Recent Developments

• Recent Developments:

• Establishment of the first mRNA vaccine manufacturing facility in Africa (BioNTainer, Rwanda) to promote scalable vaccine production.

• Introduction of new partnerships and collaborations with global pharmaceutical companies and non-profit organizations, such as Genmab, Sanofi, Regeneron, Genevant, Fosun Pharma, and Pfizer.

• Continued advancements in personalized cancer treatments with individualized mRNA-based therapies.

• Presented positive preliminary data for the first-in-class CAR-T program BNT211 in Phase 1/2 clinical trials.

• Initiation of Phase 1 clinical trial for malaria vaccine program BNT165.

Note

Fields marked as "No information is available" indicate the absence of data in the provided text.